 Process development to improve the production of therapeutically valuable proteins and monoclonal antibodies expressed in CHO cell lines (suspension cell culture) and E. coli via recombinant DNA technology.
 Process development, in process testing, scale-up and technology transfer to production, material generation for toxicology, clinical trials and dossier preparation (RCGM, PTD, TTD).
 Created technology for scale up/down model for microbial and cell culture based on hydrodynamic and geometric similarities as a function of process parameters at 2L to 500L bioreactor.
 Provide Technical and Strategic Leadership responsible for delivering Bio-similar pipeline.
 Multidisci